China Universal Asset Management Co. Ltd. Has $2.25 Million Stock Position in BioNTech SE (NASDAQ:BNTX)

China Universal Asset Management Co. Ltd. raised its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 63.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 18,939 shares of the company's stock after acquiring an additional 7,340 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in BioNTech were worth $2,249,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Covestor Ltd increased its holdings in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company's stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after acquiring an additional 388 shares during the period. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after acquiring an additional 252 shares during the last quarter. GAMMA Investing LLC raised its holdings in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company's stock worth $41,000 after purchasing an additional 238 shares during the period. Finally, Crewe Advisors LLC acquired a new stake in BioNTech in the first quarter worth $75,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Performance

NASDAQ BNTX traded up $0.75 during trading on Tuesday, reaching $114.01. The company's stock had a trading volume of 684,937 shares, compared to its average volume of 782,060. The firm has a 50 day moving average price of $107.73 and a 200 day moving average price of $95.16. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The firm has a market capitalization of $27.10 billion, a price-to-earnings ratio of 226.52 and a beta of 0.24. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same period in the prior year, the company earned ($0.86) EPS. The company's quarterly revenue was down 23.3% compared to the same quarter last year. As a group, equities analysts anticipate that BioNTech SE will post -3.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of recent analyst reports. Hsbc Global Res upgraded shares of BioNTech from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upgraded BioNTech from an "underweight" rating to a "neutral" rating and increased their price target for the stock from $91.00 to $125.00 in a report on Monday, September 16th. Bank of America boosted their price objective on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, September 16th. Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and a consensus price target of $135.54.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.